In 2019, Janssen Pharmaceuticals’ esketamine (brand name Spravato), a “chemical cousin” to ketamine, became the first new medication approved to treat clinical depression in three decades.
Meant for “treatment-resistant” depression, you take the drug nasal spray in a doctor’s office — meaning esketamine can’t be taken at home — along with your regular antidepressant.
Now, the Food and Drug Administration (FDA) approved a supplemental application to use esketamine with patients who have suicidal thoughts.
Read more on themighty.com